JLE

Hématologie

MENU

New molecular classifications of diffuse large cell lymphomas Volume 25, issue 3, Mai-Juin 2019

Figures


  • Figure 1

Tables

Author
Département d’hématologie clinique et Inserm U1245, Centre Henri Becquerel, 76038, Rouen
* Tirés à part

Diffuse large cell lymphoma (DLBCL) is the most common non-Hodgkin's lymphoma (NHL) in Western countries. More than half of its can be cured by standard immunochemotherapy treatments. About 30 to 40% will be refractory or relapsed, suggesting a high underlying biological heterogeneity. The expression profiles made it possible to understand this heterogeneity by defining the GCB/ABC subtypes. However, twenty years after its definition, the concept separating these subtypes is still ineffective for clinicians, since therapeutic trials to improve the efficacy of R-CHOP by targeting more specific alterations of the ABC subtype have all been negative to date. New classifications integrating molecular data are proposed and enrich our understanding of the heterogeneity of DLBCLs and high-grade lymphomas. They could form the basis for new approaches to stratify patients and establish therapeutic strategies.

Licence This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License